AI Project Extended to Enhance Predictions for Drug-Resistant Epilepsy
Researchers at King's College London, led by Professor Mark Richardson, have secured further funding to extend their AI-driven project aimed at identifying risk factors for drug-resistant epilepsy. The project, supported by the Epilepsy Research Institute and Angelini Pharma, will continue for an additional 16 months.
The team has developed advanced AI tools to analyze electronic health records (EHRs) from NHS hospitals. They have already annotated records of 5,556 epilepsy patients and are set to analyze an additional 4,774 records. This large-scale data analysis seeks to uncover previously unidentified risk factors for refractory epilepsy, a condition where seizures persist despite medication.
The extension will allow researchers to expand their dataset and refine AI methodologies, with a goal of analyzing up to 30,000 patient records across three London hospitals. This effort aims to provide deeper insights into the predictors of refractory epilepsy, potentially leading to new prevention strategies and personalized treatment plans.
The Epilepsy Research Institute will continue to oversee the grant and project management. This initiative highlights the collaborative effort to advance epilepsy research through innovative AI technologies and extensive data analysis.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 21 Chelsea and Westminster Hospital launches multilingual AI avatar platform for lung cancer patients Nov 21 ChatGPT Health reaches Android, desktop and dots; health chats now follow the training setting Nov 20 OpenAI launches MedChemBench to test AI models on medicinal chemistry reasoning Nov 20 Danaher and Microsoft build an agentic platform for lab instruments Nov 19 Knit Health raises $35 million to roll out its healthcare world modelLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
AI echo analysis lifts detection of a hard-to-diagnose heart failure type to 78%
UKRI names 20 Turing AI Fellows backed by more than £39M
European Laboratory for AI wins Commission call to pilot frontier AI research institute
UK commits £600 million to AI biosecurity and cyber defense
EU project ResPECT to build generative AI assistant for cancer and depression care
Daily AI Brief: the AI news that matters, in your inbox.